Pharma BD Deal Intelligence
Bayer AG secured cancer firm Algeta with a raised $2.9 billion bid; Algeta negotiated a sale price 37% over its share price just ahead of the initial approach.
A few have fretted that the company is paying a bit too much in the deal. 'The takeover price ... appears to be a bit stiff,' DZ Bank analyst Peter Spengler…
BioPharma Dive later documented the ERA-223 trial unblinding for excess fractures and deaths in the Xofigo + Zytiga combination arm — a setback that narrowed…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Bayer agreed to acquire Algeta for ~NKr17.6B (~$2.9B) on a fully-diluted basis, gaining full control of partnered prostate-cancer therapy Xofigo and Algeta's pipeline of targeted alpha radiotherapies; Bayer initial Nov bid was $2.4B, raised to $2.9B in Dec.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Algeta ASA (this deal) | 2013 | $2.9B | 38 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2013 deals · Bayer AG deals · Oncology deals